Literature DB >> 31975836

Management of Neuropsychiatric Symptoms in Neurocognitive Disorders.

Benalfew Legesse1, Baktash Babadi1, Brent Forester1.   

Abstract

Dementias, renamed neurocognitive disorders (NCDs) in the DSM-5, are defined by acquired decline in cognitive and functional abilities. DSM-5 now also includes mild NCD, which incorporates the previous diagnosis of mild cognitive impairment. DSM-5 recognizes the following etiologies for NCDs: NCD due to Alzheimer's disease, vascular NCD, NCD with Lewy bodies, frontotemporal NCD, substance-/medication-induced NCD, NCD due to traumatic brain injury, NCD due to Huntington's disease, NCD due to HIV infection, NCD due to prion disease, and NCD due to other medical conditions. In this review, the authors discuss a wide variety of interventions that have been studied for the treatment and management of neuropsychiatric symptoms of patients with NCDs. In addition to nonpharmacological interventions, several classes of medications-including antipsychotics, antidepressants, anticonvulsants, and cholinesterase inhibitors-have been studied for this indication.
Copyright © 2017 by the American Psychiatric Association.

Entities:  

Keywords:  Antidepressants; Antipsychotics; Dementia; Neurocognitive disorder; Neuropsychiatric symptoms

Year:  2017        PMID: 31975836      PMCID: PMC6519624          DOI: 10.1176/appi.focus.20160031

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  3 in total

1.  Nicotine withdrawal as an unusual cause of terminal delirium.

Authors:  Romayne Gallagher; David Williscroft
Journal:  Can Fam Physician       Date:  2022-08       Impact factor: 3.025

2.  Updates in Geriatric Psychiatry.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-07-09

Review 3.  Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases.

Authors:  Wojciech Kozubski; Kevin Ong; Wioletta Waleszczyk; Matthew Zabel; Jolanta Dorszewska
Journal:  Neural Plast       Date:  2021-03-29       Impact factor: 3.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.